Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 9/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 7/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 10/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL261446 | 0.89 | MAPT (0.46) | TP53RAB9ALMNATHRBMAPT | |
| SCHEMBL260793 | 0.86 | MAPT (0.47) | TP53RAB9ALMNATHRBMAPT | |
| SCHEMBL260581 | 0.86 | RAB9A (0.53) | TP53RAB9ALMNATHRBMAPT | |
| SCHEMBL260156 | 0.86 | MAPT (0.39) | TP53RAB9ALMNATHRBMAPT | |
| SCHEMBL260042 | 0.86 | TP53 (0.49) | TP53LMNATHRBMAPTPPARD | |
| SCHEMBL259331 | 0.85 | CDC7 (0.45) | TP53RAB9ALMNATHRBMAPT | |
| SCHEMBL264044 | 0.84 | PTGDR2 (0.41) | TP53RAB9ALMNATHRBMAPT | |
| SCHEMBL260340 | 0.84 | MAPT (0.51) | TP53LMNAMAPTPPARGPPARD | |
| SCHEMBL260007 | 0.83 | PPARD (0.53) | MAPTPPARGPPARDPPARA | |
| SCHEMBL260722 | 0.83 | MAPT (0.54) | TP53RAB9ALMNATHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498445-B2 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2009-03-03 | — | — | US | claimed |
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | claimed |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | claimed |
| US-7368577-B2 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | NOS2, NOS1, NOS3 | TP53 3723/4885RAB9A 3306/4885LMNA 4357/4885 |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | NOS2, NOS1, NOS3 | TP53 3943/4885RAB9A 3080/4885LMNA 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.